EUR 0.01
(-5.71%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 32.26 Million EUR | 23.15% |
2022 | 26.2 Million EUR | -1.27% |
2021 | 26.53 Million EUR | 23.37% |
2020 | 21.51 Million EUR | 5.73% |
2019 | 20.34 Million EUR | -4.31% |
2018 | 21.26 Million EUR | -6.7% |
2017 | 22.79 Million EUR | -2.25% |
2016 | 23.31 Million EUR | 4.85% |
2015 | 22.23 Million EUR | -33.99% |
2014 | 33.68 Million EUR | 164.25% |
2013 | 12.74 Million EUR | 8.22% |
2012 | 11.78 Million EUR | 4.79% |
2011 | 11.24 Million EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 29.8 Million EUR | -7.64% |
2024 Q2 | 29.8 Million EUR | 0.0% |
2023 Q4 | 32.26 Million EUR | 0.0% |
2023 Q3 | 32.26 Million EUR | 15.56% |
2023 FY | 32.26 Million EUR | 23.15% |
2023 Q1 | 27.92 Million EUR | 6.56% |
2023 Q2 | 27.92 Million EUR | 0.0% |
2022 Q4 | 26.2 Million EUR | 0.0% |
2022 FY | 26.2 Million EUR | -1.27% |
2022 Q2 | 21.7 Million EUR | 0.0% |
2022 Q3 | 26.2 Million EUR | 20.72% |
2021 Q2 | 17.17 Million EUR | 0.0% |
2021 Q4 | 26.53 Million EUR | 0.0% |
2021 FY | 26.53 Million EUR | 23.37% |
2020 FY | 21.51 Million EUR | 5.73% |
2020 Q4 | 21.51 Million EUR | 0.0% |
2020 Q2 | 27.22 Million EUR | 0.0% |
2019 Q4 | 20.34 Million EUR | 0.0% |
2019 Q2 | 21.98 Million EUR | 0.0% |
2019 FY | 20.34 Million EUR | -4.31% |
2018 Q2 | 20.41 Million EUR | 0.0% |
2018 FY | 21.26 Million EUR | -6.7% |
2018 Q4 | 21.26 Million EUR | 0.0% |
2017 Q4 | 22.79 Million EUR | 0.0% |
2017 FY | 22.79 Million EUR | -2.25% |
2017 Q2 | 20.94 Million EUR | 0.0% |
2016 Q2 | 20.96 Million EUR | 0.0% |
2016 Q4 | 23.31 Million EUR | 0.0% |
2016 FY | 23.31 Million EUR | 4.85% |
2015 Q2 | 16.41 Million EUR | 0.0% |
2015 Q4 | 22.23 Million EUR | 0.0% |
2015 FY | 22.23 Million EUR | -33.99% |
2014 Q4 | 33.68 Million EUR | 127.91% |
2014 Q3 | 14.78 Million EUR | 0.0% |
2014 FY | 33.68 Million EUR | 164.25% |
2013 FY | 12.74 Million EUR | 8.22% |
2013 Q4 | 12.74 Million EUR | 0.0% |
2012 FY | 11.78 Million EUR | 4.79% |
2011 FY | 11.24 Million EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
ABIONYX Pharma SA | 6.91 Million EUR | -366.782% |
ABIVAX Société Anonyme | 131.05 Million EUR | 75.381% |
Adocia SA | 31.87 Million EUR | -1.236% |
Aelis Farma SA | 13.08 Million EUR | -146.667% |
Biophytis S.A. | 15.84 Million EUR | -103.571% |
Advicenne S.A. | 24.37 Million EUR | -32.354% |
genOway Société anonyme | 14.45 Million EUR | -123.133% |
IntegraGen SA | 5.97 Million EUR | -439.55% |
Medesis Pharma S.A. | 6.42 Million EUR | -402.071% |
Neovacs S.A. | 3.71 Million EUR | -769.152% |
NFL Biosciences SA | 3.62 Million EUR | -791.103% |
Plant Advanced Technologies SA | 6.78 Million EUR | -375.705% |
Quantum Genomics Société Anonyme | 3.31 Million EUR | -874.712% |
Sensorion SA | 13.22 Million EUR | -143.92% |
Theranexus Société Anonyme | 5.01 Million EUR | -543.197% |
TME Pharma N.V. | 2.78 Million EUR | -1058.492% |
Valbiotis SA | 13.7 Million EUR | -135.366% |
TheraVet SA | 1.48 Million EUR | -2072.67% |
Valerio Therapeutics Société anonyme | 20.46 Million EUR | -57.631% |
argenx SE | 402.79 Million EUR | 91.99% |
Celyad Oncology SA | 9.97 Million EUR | -223.351% |
DBV Technologies S.A. | 38.74 Million USD | 16.728% |
Galapagos NV | 1.56 Billion EUR | 97.934% |
Genfit S.A. | 105.92 Million EUR | 69.54% |
GeNeuro SA | 20.13 Million EUR | -60.199% |
Hyloris Pharmaceuticals SA | 8.61 Million EUR | -274.64% |
Innate Pharma S.A. | 132.29 Million EUR | 75.612% |
Inventiva S.A. | 101.59 Million EUR | 68.242% |
MaaT Pharma SA | 22.46 Million EUR | -43.619% |
MedinCell S.A. | 77.77 Million EUR | 58.514% |
Nanobiotix S.A. | 95.74 Million EUR | 66.3% |
Onward Medical N.V. | 25.69 Million EUR | -25.551% |
Oryzon Genomics S.A. | 25.12 Million EUR | -28.411% |
OSE Immunotherapeutics SA | 59.07 Million EUR | 45.388% |
Oxurion NV | 19.73 Million EUR | -63.478% |
Pharming Group N.V. | 228.28 Million EUR | 85.867% |
Poxel S.A. | 53.9 Million EUR | 40.142% |
GenSight Biologics S.A. | 34.72 Million EUR | 7.092% |
Transgene SA | 26.51 Million EUR | -21.673% |
Financière de Tubize SA | 123.65 Million EUR | 73.907% |
UCB SA | 6.56 Billion EUR | 99.508% |
Valneva SE | 341.14 Million EUR | 90.542% |
Vivoryon Therapeutics N.V. | 4.54 Million EUR | -609.567% |